These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 17624310

  • 1. D-glucosamine inhibits proliferation of human cancer cells through inhibition of p70S6K.
    Oh HJ, Lee JS, Song DK, Shin DH, Jang BC, Suh SI, Park JW, Suh MH, Baek WK.
    Biochem Biophys Res Commun; 2007 Sep 07; 360(4):840-5. PubMed ID: 17624310
    [Abstract] [Full Text] [Related]

  • 2. D-glucosamine down-regulates HIF-1alpha through inhibition of protein translation in DU145 prostate cancer cells.
    Park JY, Park JW, Suh SI, Baek WK.
    Biochem Biophys Res Commun; 2009 Apr 24; 382(1):96-101. PubMed ID: 19254699
    [Abstract] [Full Text] [Related]

  • 3. ET-18-OCH3 inhibits the phosphorylation and activation of p70 S6 kinase in MCF-7 cells.
    Arthur G, Samadder P, Bittman R.
    Anticancer Res; 2005 Apr 24; 25(1A):95-100. PubMed ID: 15816524
    [Abstract] [Full Text] [Related]

  • 4. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer.
    Wang ZG, Fukazawa T, Nishikawa T, Watanabe N, Sakurama K, Motoki T, Hatakeyama S, Omori O, Ohara T, Tanabe S, Fujiwara Y, Takaoka M, Shirakawa Y, Yamatsuji T, Tanaka N, Naomoto Y.
    Oncol Rep; 2010 Apr 24; 23(4):1167-72. PubMed ID: 20204306
    [Abstract] [Full Text] [Related]

  • 5. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I.
    Endocr Relat Cancer; 2009 Sep 24; 16(3):1017-27. PubMed ID: 19509067
    [Abstract] [Full Text] [Related]

  • 6. Phorbol 12-myristate 13-acetate and serum synergize to promote rapamycin-insensitive cell proliferation via protein kinase C-eta.
    Martin PM, Aeder SE, Chrestensen CA, Sturgill TW, Hussaini IM.
    Oncogene; 2007 Jan 18; 26(3):407-14. PubMed ID: 16832347
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
    Wang Y, Zhao Q, Ma S, Yang F, Gong Y, Ke C.
    IUBMB Life; 2007 Nov 18; 59(11):717-21. PubMed ID: 17968710
    [Abstract] [Full Text] [Related]

  • 11. Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells.
    Baumann P, Mandl-Weber S, Emmerich B, Straka C, Schmidmaier R.
    Exp Cell Res; 2007 Oct 01; 313(16):3592-603. PubMed ID: 17669398
    [Abstract] [Full Text] [Related]

  • 12. Insulin-like growth factor-1 (IGF-1) and leucine activate pig myogenic satellite cells through mammalian target of rapamycin (mTOR) pathway.
    Han B, Tong J, Zhu MJ, Ma C, Du M.
    Mol Reprod Dev; 2008 May 01; 75(5):810-7. PubMed ID: 18033679
    [Abstract] [Full Text] [Related]

  • 13. TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells.
    Wang ZG, Fukazawa T, Nishikawa T, Watanabe N, Sakurama K, Motoki T, Takaoka M, Hatakeyama S, Omori O, Ohara T, Tanabe S, Fujiwara Y, Shirakawa Y, Yamatsuji T, Tanaka N, Naomoto Y.
    Oncol Rep; 2008 Dec 01; 20(6):1473-7. PubMed ID: 19020730
    [Abstract] [Full Text] [Related]

  • 14. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J.
    Cancer Res; 2008 Oct 01; 68(19):8022-30. PubMed ID: 18829560
    [Abstract] [Full Text] [Related]

  • 15. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.
    Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N.
    Cancer Res; 2007 Nov 15; 67(22):10804-12. PubMed ID: 18006825
    [Abstract] [Full Text] [Related]

  • 16. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.
    Shor B, Zhang WG, Toral-Barza L, Lucas J, Abraham RT, Gibbons JJ, Yu K.
    Cancer Res; 2008 Apr 15; 68(8):2934-43. PubMed ID: 18413763
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
    Baumann P, Mandl-Weber S, Oduncu F, Schmidmaier R.
    Exp Cell Res; 2009 Feb 01; 315(3):485-97. PubMed ID: 19071109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.